Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Rectal Neoplasms 1Neoplasms 1Melanoma 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

pembrolizumab 300Nivolumab 273Ipilimumab 250aldesleukin 137Cyclophosphamide 136Interleukin-2 105trametinib 82dabrafenib 76Temozolomide 75Dacarbazine 74Vemurafenib 71fludarabine 68fludarabine phosphate 62Biopsy 49binimetinib 47sargramostim 44Radiosurgery 44Bevacizumab 43Paclitaxel 42encorafenib 40incomplete Freund's adjuvant 39atezolizumab 38Radiotherapy 37Specimen Handling 36Cisplatin 36CTLA-4 Antigen 36Magnetic Resonance Spectroscopy 35Carboplatin 35cobimetinib 34Introns 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × nanocis × Clear all
NCT02997553 2023-01-09

GASVERT

Institut de Cancérologie de Lorraine

Phase 3 Completed
744 enrolled
BreastDermatologicGastrointestinalGynecologicHead & Neck

Anus Neoplasms, Breast Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Rectal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡